Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2 81,"Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,259 days to 143 days,22,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,,,94,%,,,MMO:0000158,manual palpation method,,0,,crystalline implant,,,17 beta-estradiol (27.5 mg) (between 193 and 199 days),65764,17 beta-estradiol (27.5 mg) (between 193 and 199 days), 81,"Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800",mammary gland integrity trait,,RS:0000155,BN/SsNHsd,female,259 days,13,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,,,0,%,,,MMO:0000158,manual palpation method,,0,,crystalline implant,,,17 beta-estradiol (27.5 mg) (between 196 and 199 days),65765,17 beta-estradiol (27.5 mg) (between 196 and 199 days), 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0000809,SS-Chr 9BN/Mcwi,female,162 days to 152 days,40,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,,,93,%,,,MMO:0000158,manual palpation method,,0,200 mg DMBA in 10 ml seame oil,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",11495,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)", 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0000806,SS-Chr 6BN/Mcwi,female,162 days to 152 days,20,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,,,20,%,,,MMO:0000158,manual palpation method,,0,200 mg DMBA in 10 ml seame oil,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",11494,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)", 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0000805,SS-Chr 5BN/Mcwi,female,162 days to 152 days,13,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,,,54,%,,,MMO:0000158,manual palpation method,,0,200 mg DMBA in 10 ml seame oil,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 g/kg) (for 105 days)",11493,"7,12-dimethyltetraphene (DMBA) (65 g/kg) (for 105 days)", 76,"Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,203 days to 201 days,11,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,,,0,%,,,MMO:0000158,manual palpation method,mammary gland,0,,,,,bilateral ovariectomy then 17 beta-estradiol (27.5 mg) (for 140 days),11379,bilateral ovariectomy,17 beta-estradiol (27.5 mg) (for 140 days) 76,"Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,518 days to 201 days,3,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,,,0,%,,,MMO:0000158,manual palpation method,mammary gland,0,,,,,control condition,11378,control condition, 76,"Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,260 days to 160 days,21,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,,,100,%,,,MMO:0000158,manual palpation method,mammary gland,0,,,,,17 beta-estradiol (27.5 mg) (for 197 days),65549,17 beta-estradiol (27.5 mg) (for 197 days), 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0000803,SS-Chr 3BN/Mcwi,female,162 days to 152 days,14,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,,,29,%,,,MMO:0000158,manual palpation method,,0,200 mg DMBA in 10 ml seame oil,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",65566,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)", 144,"Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30",mammary gland integrity trait,,RS:0000186,COP/OlaHsd,female,330 days to 212 days,7,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,mean,,43.8,%,,,MMO:0000158,manual palpation method,,0,,,,,17 beta-estradiol (27.5 mg) (between 212 and 330 days),66113,17 beta-estradiol (27.5 mg) (between 212 and 330 days), 144,"Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,264 days to 206 days,31,,CMO:0000948,percentage of study population developing mammary tumors during a period of time,,mean,,100,%,,,MMO:0000158,manual palpation method,,0,,,,,17 beta-estradiol (27.5 mg) (between 147 and 195 days),66112,17 beta-estradiol (27.5 mg) (between 147 and 195 days),